Can a new pill lift the fog of depression?

NCT ID NCT07772531

NEW Not yet recruiting Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Aug 19, 2026 · Last updated Aug 19, 2026

Summary

This phase 2 trial is testing whether an experimental drug called BMS-986511 can reduce symptoms of major depressive disorder in adults. Participants with moderate to severe depression will receive either the drug or a placebo, and researchers will track changes in depression scores and any side effects. The goal is to see if this drug offers a safe and effective new way to manage depression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called BMS-986511 (also known as Evifacotrep)
What this could lead to: If successful, this could point toward a new treatment option for people with major depressive disorder who need better symptom relief.
What could go wrong: This is an early-phase trial with a modest number of participants, so results may not hold up in larger studies. The drug may also cause side effects, and not everyone may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression major depressive disorder mood disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSIVE DISORDER

Contacts and locations

Locations

Local Institution - 0003

Everett, Washington, 98201, United States
Local Institution - 0005

Kladno, 27201, Czechia
Local Institution - 0007

Jacksonville, Florida, 32256, United States
Local Institution - 0016

Dallas, Texas, 75231, United States
Local Institution - 0024

Orlando, Florida, 32801, United States
Local Institution - 0027

Oklahoma City, Oklahoma, 73112, United States
Local Institution - 0028

Pilsen, 31200, Czechia
Local Institution - 0032

Prague, Praha 8, 18600, Czechia
Local Institution - 0038

Little Rock, Arkansas, 72211, United States
Local Institution - 0041

Cedarhurst, New York, 11516, United States
Local Institution - 0042

Glendale, California, 91206, United States
Local Institution - 0044

Gaithersburg, Maryland, 20877, United States
Local Institution - 0046

Garden Grove, California, 92845, United States
Local Institution - 0047

Rogers, Arkansas, 72758, United States
Local Institution - 0050

Upland, California, 91786, United States
Local Institution - 0069

Mount Kisco, New York, 10549, United States
Local Institution - 0071

Lemon Grove, California, 91945, United States
Local Institution - 0075

Boston, Massachusetts, 02135, United States
Local Institution - 0079

Oakland, California, 94607, United States
Local Institution - 0080

Prague, 10000, Czechia
Local Institution - 0081

Klecany, 25067, Czechia
Local Institution - 0083

Cincinnati, Ohio, 45219, United States
Local Institution - 0086

Columbus, Ohio, 43210, United States
Local Institution - 0111

Prague, Praha 6, 16000, Czechia
Local Institution - 0121

Staten Island, New York, 10312, United States
Local Institution - 0144

Phoenix, Arizona, 85012, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.